566 related articles for article (PubMed ID: 16294904)
21. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Mantovani C; Fiandra C; Anglesio S; Ragona R
Acta Oncol; 2009; 48(4):571-7. PubMed ID: 19031164
[TBL] [Abstract][Full Text] [Related]
22. A TCP-NTCP estimation module using DVHs and known radiobiological models and parameter sets.
Warkentin B; Stavrev P; Stavreva N; Field C; Fallone BG
J Appl Clin Med Phys; 2004; 5(1):50-63. PubMed ID: 15753933
[TBL] [Abstract][Full Text] [Related]
23. Comparison between the ideal reference dose level and the actual reference dose level from clinical 3D radiotherapy treatment plans.
Bufacchi A; Arcangeli G; delle Canne S; Malatesta T; Capparella R; Fragomeni R; Marmiroli L; Begnozzi L
Radiother Oncol; 2009 Jul; 92(1):68-75. PubMed ID: 19328571
[TBL] [Abstract][Full Text] [Related]
24. [Reirradiation of normal tissues: preclinical radiobiological data].
Bourgier C; Vozenin MC; Deutsch E
Cancer Radiother; 2010 Oct; 14(6-7):412-5. PubMed ID: 20727804
[TBL] [Abstract][Full Text] [Related]
25. [Prevention of radiation injuries during multifractionation in radiation therapy].
Zholkiver KI; Zevrieva IF
Med Radiol (Mosk); 1983 Apr; 28(4):3-6. PubMed ID: 6835069
[TBL] [Abstract][Full Text] [Related]
26. Number of patients potentially eligible for proton therapy.
Glimelius B; Ask A; Bjelkengren G; Björk-Eriksson T; Blomquist E; Johansson B; Karlsson M; Zackrisson B
Acta Oncol; 2005; 44(8):836-49. PubMed ID: 16332591
[TBL] [Abstract][Full Text] [Related]
27. [Probabilities of controlling tumors and complications (TCP/NTCP) after radiotherapy: methodologic, physical, and biological aspects].
Kulik C; Mazurier J; Lartigau E
Cancer Radiother; 2002 Nov; 6 Suppl 1():155s-165s. PubMed ID: 12587394
[TBL] [Abstract][Full Text] [Related]
28. The use of spatial dose gradients and probability density function to evaluate the effect of internal organ motion for prostate IMRT treatment planning.
Jiang R; Barnett RB; Chow JC; Chen JZ
Phys Med Biol; 2007 Mar; 52(5):1469-84. PubMed ID: 17301465
[TBL] [Abstract][Full Text] [Related]
29. Comparison of predicted and clinical response to radiotherapy: a radiobiology modelling study.
Hedman M; Bjork-Eriksson T; Mercke C; West C; Hesselius P; Brodin O
Acta Oncol; 2009; 48(4):584-90. PubMed ID: 19107620
[TBL] [Abstract][Full Text] [Related]
30. Normal tissue complication probability modelling of tissue fibrosis following breast radiotherapy.
Alexander MA; Brooks WA; Blake SW
Phys Med Biol; 2007 Apr; 52(7):1831-43. PubMed ID: 17374914
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic use of fast neutrons in oncology].
Ruderman AI; Makarova GV
Vopr Onkol; 1977; 23(4):97-111. PubMed ID: 329580
[No Abstract] [Full Text] [Related]
32. Biological mechanisms of normal tissue damage: importance for the design of NTCP models.
Trott KR; Doerr W; Facoetti A; Hopewell J; Langendijk J; van Luijk P; Ottolenghi A; Smyth V
Radiother Oncol; 2012 Oct; 105(1):79-85. PubMed ID: 22748390
[TBL] [Abstract][Full Text] [Related]
33. Convex reformulation of biologically-based multi-criteria intensity-modulated radiation therapy optimization including fractionation effects.
Hoffmann AL; den Hertog D; Siem AY; Kaanders JH; Huizenga H
Phys Med Biol; 2008 Nov; 53(22):6345-62. PubMed ID: 18941280
[TBL] [Abstract][Full Text] [Related]
34. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD).
Luxton G; Keall PJ; King CR
Phys Med Biol; 2008 Jan; 53(1):23-36. PubMed ID: 18182685
[TBL] [Abstract][Full Text] [Related]
35. Normal tissue tolerance and damage.
Cancer; 1976 Apr; 37(4 Suppl):2046-55. PubMed ID: 1260701
[No Abstract] [Full Text] [Related]
36. Development of radiobiology for oncology-a personal view.
Fowler JF
Phys Med Biol; 2006 Jul; 51(13):R263-86. PubMed ID: 16790907
[TBL] [Abstract][Full Text] [Related]
37. Preoperative radiation treatment for rectal cancer: comparison of target coverage and small bowel NTCP in conventional vs. 3D-conformal planning.
Cella L; Ciscognetti N; Martin G; Liuzzi R; Punzo G; Solla R; Farella A; Salvatore M; Pacelli R
Med Dosim; 2009; 34(1):75-81. PubMed ID: 19181259
[TBL] [Abstract][Full Text] [Related]
38. Intensity modulated radiation therapy (IMRT)--a new approach to external beam RT.
Hevezi JM; Morin RL
J Am Coll Radiol; 2004 Mar; 1(3):221-2. PubMed ID: 17411565
[No Abstract] [Full Text] [Related]
39. Normal tissue tolerance dose metrics for radiation therapy of major organs.
Milano MT; Constine LS; Okunieff P
Semin Radiat Oncol; 2007 Apr; 17(2):131-40. PubMed ID: 17395043
[TBL] [Abstract][Full Text] [Related]
40. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
